SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing intense volatility as investors weigh a major strategic partnership and infrastructure deal with NVIDIA against broader market concerns and concerns over financial dilution. The community is sharply divided, with bulls pointing to the company's long-term pivot to AI data centers as a massive catalyst, while bears are expressing skepticism over recent earnings and questioning the tangible impact of the announced agreements.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently the top trending stock as investors anticipate its Q1 earnings, fueled by optimism over a record $2.2 billion backlog and significant defense contracts, including a new partnership with Anduril. The community is actively debating the stock's potential to reach triple digits, with bullish sentiment driven by the company's aggressive vertical integration strategy and its perceived position as the primary Western competitor to SpaceX.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is surging following strong Q1 earnings that beat revenue and EPS estimates, alongside raised full-year guidance and new enterprise AI engagements. The community is actively discussing a potential short squeeze due to significant short interest and a low float, with many bulls holding for further gains while skeptics advise caution.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors weigh strong quarterly revenue performance and a strategic pivot toward prediction markets against ongoing regulatory scrutiny and increased competition. The community remains divided, with some bulls highlighting the company's path to profitability and potential for long-term growth, while others express frustration over stagnant price action, insider selling, and the emerging threat of alternative betting platforms.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors rally behind its pivot to a "Physical AI" and robotics infrastructure play, fueled by strong institutional interest and anticipation of its critical role in autonomous systems. Community members are actively highlighting the company's deep automotive backlog and cybersecurity credentials, with many expressing long-term optimism regarding a potential breakout driven by these strategic shifts.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as shareholders react to a recent lawsuit filed against distribution partner Nippon Shinyaku, with the community interpreting the move as a strategic effort to regain full control of deramiocel ahead of an anticipated August FDA decision. While some investors express short-term concern over legal uncertainty, many are using the pullback as a buying opportunity, viewing the litigation as a necessary maneuver to improve commercial economics and clear the path for a potential acquisition or independent launch.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the center of intense trading volume and community speculation, fueled by strong recent performance and rumors of strategic expansion projects. Traders are actively debating the stock's valuation as long-term investors weigh the company's innovation pipeline against retail exuberance and a heavy focus on short-term call options.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors aggressively bid up memory chip stocks, fueled by an AI-driven supercycle and the perception that the company is significantly undervalued relative to its forward growth potential. The community is actively debating the stock's long-term sustainability, with many traders leaning into a "buy the dip" mentality while others caution against potential volatility and valuation concerns.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing extreme volatility as investors express deep frustration over a sequence of disappointing earnings reports and slowing growth, with many in the community calling for leadership changes. While some long-term holders see value in the company's cash position and potential AI integration, others are bracing for further downside amid concerns regarding market share losses and executive departures.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is drawing significant investor interest as it trades near multi-year lows, sparking intense community debate over potential catalysts like a leadership appointment, a strategic buyout, or an aggressive short squeeze. Traders are actively weighing the company's turnaround efforts, including international expansion plans and operational improvements, against concerns over high debt and recent same-store sales performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Artiva reported positive early clinical data for its AlloNK cell therapy in patients with difficult-to-treat rheumatoid arthritis and other autoimmune diseases.</li><li>The U.S. Food and Drug Administration has aligned with the biotech firm on a single Phase 3 registrational trial.</li><li>Artiva reported a loss of $0.95 per share, compared to estimates of a loss of $0.86 per share.</li></ul>Shares of Artiva Biotherapeutics (ARTV) pared early premarket gains on Friday, after a discounted $300 million public offering and a wider-than-expected first-quarter (Q1) loss weighed on sentiment even as the biotech firm announced promising clinical results for its rheumatoid arthritis and autoimmune disease therapy.On Friday, Artiva reported a net loss of $23.5 million, or $0.95 per share, wider than analysts’ expectations of a loss of $0.86 per share, according to Fiscal.ai data.<h2 class="st-heading-2">ARTV’s Phase 2 Trial Shows Significant Symptom Improvement</h2>Artiva reported positive early clinical data for its AlloNK cell therapy in patients with difficult-to-treat rheumatoid arthritis (RA) and other autoimmune diseases. In the ongoing Phase 2a trial, 71% of refractory RA patients with at least six months of follow-up achieved an ACR50 response, a key measure showing significant symptom improvement.The company said no patients relapsed or required additional treatments during follow-up. Artiva also highlighted favorable safety and tolerability results for the AlloNK plus Rituximab drug treatment regimen.No cases of cytokine release syndrome (CRS), neurotoxicity (ICANS), or treatment discontinuations were reported, supporting the potential for outpatient use in community rheumatology clinics.More than 70 autoimmune patients have been treated with AlloNK across over 40 active clinical sites globally. The U.S. Food and Drug Administration (FDA) has aligned with Artiva on a single Phase 3 registrational trial comparing AlloNK plus Rituximab against Rituximab alone in about patients. The company plans to begin the trial in the second half of 2026.<h2 class="st-heading-2">ARTV’s $300M Offering</h2>Separately, the biotech firm announced the pricing of an underwritten public offering that is expected to raise about $300 million in gross proceeds. The company is set to sell nearly 23.9 million shares of common stock at $11.52 per share, along with pre-funded warrants to purchase about 2.17 million additional shares for certain investors. This represents a 9% discount from the stock’s Thursday closing price.Artiva said all securities in the offering are being sold directly by the company to support the development of its autoimmune disease therapies.<h2 class="st-heading-2">What Does Retail Think Of ARTV?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/ARTV">ARTV</a> on Stocktwits remained in the ‘extremely bullish’ territory over the past 24 hours, while message volumes were ‘high.’One user called the Phase 3 approval “solid news” and expected the stock to rally after breaking past $16.<stembedurl>https://stocktwits.com/The_Assassin/message/652705720</stembedurl>The stock has gained more than 190% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-price-rocket-lab-q1-earnings-analyst-price-targets/cZX2jVZReXw">RKLB Stock Is Back In Rally Mode After Q1 Earnings – And Retail Traders Want $100 Next</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ARTV Stock Pares Majority Of Pre-Market Gains – $300M Offering Overshadows Strong Data For Rheumatoid Arthritis Therapy

Artiva announced a $300 million public offering to support the development of its autoimmune disease therapies, but at a 9% discount per share compared to Thursday’s closing price.

Equity

Artiva Biotherapeutics Prices $300 Mln Stock, Pre-Funded Warrants Offering; Shares Rise

(RTTNews) - Artiva Biotherapeutics, Inc. (ARTV), a clinical-stage biotechnology company, on Friday announced the pricing of an underwritten offering of stock and pre-funded warrants...

Artiva Biotherapeutics (NASDAQ:ARTV) Earns "Buy" Rating from Needham & Company LLC

Needham & Company LLC reissued a "buy" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Monday...

Artiva Biotherapeutics (NASDAQ:ARTV) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded Artiva Biotherapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday...

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Analysts

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five analysts that are covering the stock, Marketbeat.com reports. One...

Artiva Biotherapeutics (NASDAQ:ARTV) Raised to "Hold" at Wall Street Zen

Wall Street Zen upgraded shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research report on Monday...

Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham

Artiva Biotherapeutics (NASDAQ:ARTV) is prioritizing rheumatoid arthritis (RA) as the lead indication for its non-genetically modified natural killer (NK) cell therapy platform, executives said...

Artiva Biotherapeutics (NASDAQ:ARTV) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered Artiva Biotherapeutics from a "hold" rating to a "sell" rating in a research note on Sunday...

Artiva Biotherapeutics (NASDAQ:ARTV) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday...

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are currently covering the firm, Marketbeat...

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

Bullish

Neutral

Bearish

On the sidelines

How do you feel about the market right now?

Stocktwits

Stocktwits Polls

Traders are closely watching the $300M share offering at $11.52, debating if the expected supply increase will trigger a sharp sell-off at market open.

The stock is seeing significant interest following FDA alignment for a registrational Phase 3 trial of the AlloNK autoimmune therapy.

Current Price	$11.57
Prev Close	$12.52
Open	$12.05
Dividend Yield	0.00%
50-Day Moving Average	$7.80
Beta	1.51
Avg. Volume	356,889.08
PE Ratio	-3.65

52-Week High	$14.53
52-Week Low	$1.47
Market Capitalization	$309.45M
EPS (Annual)	-$3.43
Price to Book	2.80
Revenue Per Employee	$0.00

ARTV
Artiva Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARTV News

ARTVArtiva Biotherapeutics Inc